NA 808

Drug Profile

NA 808

Alternative Names: NA808

Latest Information Update: 29 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus replication inhibitors; Serine palmitoyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 29 Aug 2012 Discontinued - Phase-I for Hepatitis C in Japan (Parenteral) before 2012
  • 29 Aug 2012 Discontinued - Phase-I for Hepatitis C in USA (Parenteral) before 2012
  • 10 Feb 2011 Suspended - Phase-I for Hepatitis C in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top